News

An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

International investigators observe differing levels of severe COVID-19 risk for patients with atopic dermatitis, dependent on their current therapy.

Data from the phase 3 TRuE-V clinical program show the topical JAK inhibitor provided substantial repigmentation to more than half of treated patients.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

Dupilumab is the first biologic to show positive phase 3 results in patients with prurigo nodularis.

A Perelman School of Medicine assessment of biopsy rates support previous findings showing that dermatologists are less confident making psoriasis diagnoses in patients with darker skin color.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.

The relative risk of hospitalization was substantially lower for patients with IBD and COVID-19 who were treated with biologics (compared to patients not treated with biologics.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

The advent of biologics has transformed care for patients with inflammatory bowel disease.

Severe and level 2 hypoglycemia has continued to occur in individuals with type 1 diabetes and high hypoglycemia risks despite technological advancements.

There is a need to study more combination therapies for the treatment of inflammatory bowel disease.

Interstitial lung disease expert explains the importance of educating patients with autoimmune disease.

Dr. Elena B. Hawryluk details her pre-AAD session, the variety of conversations being held at the meeting, and how these conversations can inform dermatological research outside of the pediatric field.

RBX2660 is a live microbiome therapeutics that could build on the success of fecal microbiota transplantation for treating patients with recurrent C difficile infections.

Data from Australia show a T-cell antigen-inducing vaccine was unable to provide greater prevention of flu incidence than a placebo.

Large variations were observed in the transition between monotherapy and dual combination therapy for hypertension across countries and demographic group.

Dr. Rees spoke of how addressing issues of representation could improve upon disparities in health care not only in the pediatric space but across all fields.

IL-17 inhibitors were also associated with higher persistence than IL-12 and IL-23 inhibitors for psoriatic arthritis, though no difference was observed for psoriasis.

There was an independent association between in-hospital mortality and a neutrophil ratio greater than 75%, serum creatinine of at least 1.5 mg/L, and CDI caused by isolates harboring the tcdC gene.

Strategies to improve enrollment of underrepresented populations were centered on study design and site selection, community engagement, and changing the research paradigm.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

Case-control analyses suggest older patients may cognitively age by about 8 years within 6 months of being discharged for severe COVID-19.